FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2255363071> ?p ?o ?g. }

• W2255363071 endingPage "858" @default.
• W2255363071 startingPage "849" @default.
• W2255363071 abstract "Some compounds of a series of novel pyrrolo-1,5-benzoxa(thia)zepine, a well-known group of tubulin targeting agents, display anti-tumor effects mainly inducing cell cycle arrest and apoptosis in several human cancer models. A member of this family, pyrrolo-1,5-benzoxazepine-15 (PBOX-15), has previously shown potent pro-apoptotic activity in a variety of human tumor cell types, with minimal toxicity toward normal blood and bone marrow cells. In this study, we evaluated the PBOX-15-mediated effects in human colorectal cancer cell (CRC) lines, DLD-1 and HT-29. The compound, used at concentrations equal to or greater than 1 μM, inhibited the proliferation of human CRC cells, inducing a significant cell cycle arrest in the G2/M phase. In DLD-1 cells, treatments prolonged over 48 h triggered a strong activation of the intrinsic apoptotic pathway as indicated by activation of caspase-9, caspase-3 and PARP cleavage. Moreover, nanomolar concentrations of PBOX-15, significantly improved the oxaliplatin and 5-fluouracil-induced anti-proliferative effects in DLD1 cell line. The observed synergistic interaction of both PBOX-15/Oxaliplatin and PBOX-15/5FU may involve activation of p38 MAPK and JNK pathway, which in turn significantly increased caspase-3 cleavage in DLD-1 cells, treated with PBOX-5/Oxaliplatin but not with PBOX-15/5FU. Moreover, PBOX-15/5FU-treated cells showed an increase in expression of the pro-apoptotic protein Bax. Taken together, these results show that PBOX-15 could represent a promising compound for the treatment of human CRC and a strong candidate for novel therapeutic options." @default.
• W2255363071 created "2016-06-24" @default.
• W2255363071 creator A5004950855 @default.
• W2255363071 creator A5007484138 @default.
• W2255363071 creator A5008119223 @default.
• W2255363071 creator A5015069863 @default.
• W2255363071 creator A5023657474 @default.
• W2255363071 creator A5025430127 @default.
• W2255363071 creator A5026142881 @default.
• W2255363071 creator A5027382532 @default.
• W2255363071 creator A5038347649 @default.
• W2255363071 creator A5041053388 @default.
• W2255363071 creator A5044789260 @default.
• W2255363071 creator A5049005627 @default.
• W2255363071 creator A5052364748 @default.
• W2255363071 creator A5068513157 @default.
• W2255363071 creator A5072264240 @default.
• W2255363071 creator A5075042666 @default.
• W2255363071 creator A5080795452 @default.
• W2255363071 creator A5084867757 @default.
• W2255363071 date "2015-09-21" @default.
• W2255363071 modified "2023-09-26" @default.
• W2255363071 title "Antitumor effect of pyrrolo-1,5-benzoxazepine-15 and its synergistic effect with Oxaliplatin and 5-FU in colorectal cancer cells" @default.
• W2255363071 cites W1576305824 @default.
• W2255363071 cites W1579431026 @default.
• W2255363071 cites W1971964434 @default.
• W2255363071 cites W1972188075 @default.
• W2255363071 cites W1974297564 @default.
• W2255363071 cites W1991170299 @default.
• W2255363071 cites W1992361007 @default.
• W2255363071 cites W1996979563 @default.
• W2255363071 cites W1998782430 @default.
• W2255363071 cites W2004700438 @default.
• W2255363071 cites W2012424371 @default.
• W2255363071 cites W2019927938 @default.
• W2255363071 cites W2033362135 @default.
• W2255363071 cites W2035916997 @default.
• W2255363071 cites W2047717400 @default.
• W2255363071 cites W2051486692 @default.
• W2255363071 cites W2053385355 @default.
• W2255363071 cites W2054239953 @default.
• W2255363071 cites W2066370617 @default.
• W2255363071 cites W2075085587 @default.
• W2255363071 cites W2077945404 @default.
• W2255363071 cites W2083911670 @default.
• W2255363071 cites W2086066816 @default.
• W2255363071 cites W2103155309 @default.
• W2255363071 cites W2113919377 @default.
• W2255363071 cites W2116619455 @default.
• W2255363071 cites W2118884411 @default.
• W2255363071 cites W2128403792 @default.
• W2255363071 cites W2130392703 @default.
• W2255363071 cites W2145443633 @default.
• W2255363071 cites W2152670310 @default.
• W2255363071 cites W2153127782 @default.
• W2255363071 cites W2167504781 @default.
• W2255363071 cites W2170486320 @default.
• W2255363071 cites W2171232394 @default.
• W2255363071 cites W4236891330 @default.
• W2255363071 doi "https://doi.org/10.1080/15384047.2015.1078028" @default.
• W2255363071 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5004676" @default.
• W2255363071 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26392056" @default.
• W2255363071 hasPublicationYear "2015" @default.
• W2255363071 type Work @default.
• W2255363071 sameAs 2255363071 @default.
• W2255363071 citedByCount "17" @default.
• W2255363071 countsByYear W22553630712016 @default.
• W2255363071 countsByYear W22553630712017 @default.
• W2255363071 countsByYear W22553630712019 @default.
• W2255363071 countsByYear W22553630712020 @default.
• W2255363071 countsByYear W22553630712021 @default.
• W2255363071 countsByYear W22553630712022 @default.
• W2255363071 countsByYear W22553630712023 @default.
• W2255363071 crossrefType "journal-article" @default.
• W2255363071 hasAuthorship W2255363071A5004950855 @default.
• W2255363071 hasAuthorship W2255363071A5007484138 @default.
• W2255363071 hasAuthorship W2255363071A5008119223 @default.
• W2255363071 hasAuthorship W2255363071A5015069863 @default.
• W2255363071 hasAuthorship W2255363071A5023657474 @default.
• W2255363071 hasAuthorship W2255363071A5025430127 @default.
• W2255363071 hasAuthorship W2255363071A5026142881 @default.
• W2255363071 hasAuthorship W2255363071A5027382532 @default.
• W2255363071 hasAuthorship W2255363071A5038347649 @default.
• W2255363071 hasAuthorship W2255363071A5041053388 @default.
• W2255363071 hasAuthorship W2255363071A5044789260 @default.
• W2255363071 hasAuthorship W2255363071A5049005627 @default.
• W2255363071 hasAuthorship W2255363071A5052364748 @default.
• W2255363071 hasAuthorship W2255363071A5068513157 @default.
• W2255363071 hasAuthorship W2255363071A5072264240 @default.
• W2255363071 hasAuthorship W2255363071A5075042666 @default.
• W2255363071 hasAuthorship W2255363071A5080795452 @default.
• W2255363071 hasAuthorship W2255363071A5084867757 @default.
• W2255363071 hasBestOaLocation W22553630711 @default.
• W2255363071 hasConcept C105696609 @default.
• W2255363071 hasConcept C121608353 @default.
• W2255363071 hasConcept C12519072 @default.
• W2255363071 hasConcept C126322002 @default.
• W2255363071 hasConcept C185592680 @default.

• next